Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in ...

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals ... around 115 million people in the US, and standard therapy is eradication with a combination ...

It's never finished but I think we have made great steps forward. Related stories Insider: You mention the Shire acquisition. How important has that been for Takeda's global transformation journey?

Takeda Pharmaceutical said on Thursday its CEO ... nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to ...

Julie Kim is set to replace Christophe Weber as the new CEO of Takeda Pharmaceutical, becoming the first woman to lead the more than 240-year-old Japanese drugmaker. Kim, 54, has been running ...